Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a rare but severe immune disorder characterized by excessive immune system activation and progressive tissue damage. Primary HLH occurs in approximately 1 in 50,000 births worldwide. Hemophagocytic lymphohistiocytosis therapeutic products include targeted biologics, immunosuppressants, and emerging gene therapies designed to regulate abnormal immune responses. With increasing focus on early diagnosis, expanding clinical research, and advancements in precision medicine, the HLH treatment landscape is rapidly advancing. Hemophagocytic lymphohistiocytosis pipeline analysis by Expert Market Research highlights key therapies in development and the potential for significant growth in the coming years.
Major companies involved in the hemophagocytic lymphohistiocytosis pipeline analysis include Incyte Corporation, Swedish Orphan Biovitrum, and others.
Leading drugs currently in the pipeline include Emapalumab, ELA026, and others.
Rising clinical trial activity for anti-IFNγ monoclonal antibodies, advancement in gene therapy research targeting PRF1 mutations, and increased funding are expected to accelerate pipeline development significantly.
The Hemophagocytic Lymphohistiocytosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hemophagocytic lymphohistiocytosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hemophagocytic lymphohistiocytosis. The hemophagocytic lymphohistiocytosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hemophagocytic lymphohistiocytosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hemophagocytic lymphohistiocytosis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hemophagocytic lymphohistiocytosis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of excessive immune activation. It occurs when the body’s immune system fails to regulate itself, leading to severe inflammation and tissue damage. HLH can be inherited (primary) or acquired (secondary) and is commonly associated with infections, autoimmune disorders, or malignancies. Symptoms include persistent high fever, enlarged liver or spleen, and blood abnormalities.
Hemophagocytic lymphohistiocytosis treatment typically involves immunosuppressive therapies such as corticosteroids, etoposide, and cyclosporine. In refractory cases, targeted therapies like emapalumab and hematopoietic stem cell transplantation are required. In February 2025, the U.S. Food and Drug Administration granted Priority Review to Sobi’s supplemental Biologics License Application for Gamifant® (emapalumab-lzsg) to treat hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease patients unresponsive or intolerant to glucocorticoids.
Hemophagocytic Lymphohistiocytosis (HLH) remains rare, with primary HLH affecting 1 in 50,000 births globally. A study from 2011-2018 identified 939 adult HLH hospitalizations, with a mean age of 28 years. Hospitalizations rose from 96 to 150, with a 16% mortality rate and a downward trend. The mean stay was 19.4 days, while charges increased significantly. Epstein-Barr Virus and lymphoma were linked to 5.92% and 1.16% of cases, respectively.
This section of the report covers the analysis of hemophagocytic lymphohistiocytosis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 39.29%, covers a major share of the total hemophagocytic lymphohistiocytosis clinical trials, highlighting strong ongoing efforts in developing effective therapies for hemophagocytic lymphohistiocytosis. Phase I accounts for 32.14%, followed by phase III at 17.86%, and phase IV at 10.71%. These advancing trials reflect promising therapeutic progress, potentially transforming patient care and significantly impacting the hemophagocytic lymphohistiocytosis pipeline growth.
The drug molecule categories covered under the hemophagocytic lymphohistiocytosis pipeline analysis include small molecules, biologics, gene therapies, and monoclonal antibodies. The hemophagocytic lymphohistiocytosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hemophagocytic lymphohistiocytosis.
Kinase inhibitors are gaining prominence in the treatment of hemophagocytic lymphohistiocytosis (HLH) due to their targeted mechanism of action. For instance, a phase II trial is evaluating ruxolitinib, a Janus kinase (JAK) inhibitor, in combination with a de-intensified HLH-94 regimen. This combination aims to reduce inflammatory signaling while maintaining therapeutic efficacy and minimizing treatment-related toxicity in adult HLH patients.
The EMR report for the hemophagocytic lymphohistiocytosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hemophagocytic lymphohistiocytosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hemophagocytic lymphohistiocytosis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hemophagocytic lymphohistiocytosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hemophagocytic lymphohistiocytosis drug candidates.
Emapalumab, sponsored by Swedish Orphan Biovitrum, is a monoclonal antibody targeting interferon-gamma (IFNγ), aiming to reduce inflammation in primary hemophagocytic lymphohistiocytosis (pHLH). It is a part of a Phase IV, open-label, multi-centre study that is currently evaluating its safety and efficacy in treatment-experienced Chinese patients with confirmed or suspected pHLH, collecting vital post-authorization data to support continued therapeutic use.
ELA026 is being evaluated by Electra Therapeutics Inc. in an open-label Phase II/III study for secondary hemophagocytic lymphohistiocytosis (sHLH). This trial is assessing the safety, efficacy, pharmacokinetics, and pharmacodynamics of ELA026, a fully human IgG1 monoclonal antibody. The drug targets myeloid and T cells, driving inflammation while preserving immune checkpoint balance.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hemophagocytic Lymphohistiocytosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hemophagocytic lymphohistiocytosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hemophagocytic lymphohistiocytosis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share